A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
|Articles|January 20, 2022
Daily Medication Pearl: Cyclosporine Ophthalmic Solution (Cequa)
Author(s)Saro Arakelians, PharmD
Cequa ophthalmic solution is indicated to increase tear production in patients with dry eyes.
Advertisement
Medication Pearl of the Day: Cyclosporine ophthalmic solution (Cequa)
Indication: Cequa ophthalmic solution is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eyes).
Insight:
- Dosing: Instill 1 drop of Cequa twice daily (approximately 12 hours apart) into each eye. Discard the vial immediately after using in both eyes.
- Dosage forms: Ophthalmic solution containing cyclosporine 0.9 mg/mL.
- Adverse events (AEs): The most common AEs reported in greater than 5% of subjects were pain on instillation of drops (22%) and conjunctival hyperemia (6%). Other AEs reported in 1% to 5% of the patients were blepharitis, eye irritation, headache, and urinary tract infection.
- Mechanism of action: Cyclosporine is a calcineurin inhibitor immunosuppressant agent when administered systemically.
- Manufacturer: Sun Pharma
Sources:
Advertisement
Related to this article
A Novo Nordisk-funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, though the findings cannot show causation.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg versus placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
September 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
Orforglipron Edges Oral Semaglutide 25 mg in T2D, Indirect Comparison Finds
4
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
5